Skip to main content

LEO Pharma helps patients to be #PsoInControl and get the confidence to better manage their psoriasis

LEO Pharma encourages psoriasis sufferers to get the confidence to take control as part of World Psoriasis Day’s theme of “Breaking Barriers For People With Psoriasis!”

TORONTO, ON -- (October 17, 2016) - LEO Pharma’s focus is to provide people affected by psoriasis with resources to get the confidence to better manage their lives and thereby help breaking barriers that they may face as individuals.

World Psoriasis Day (WPD) is an annual day specially dedicated to people with psoriasis created by the International Federation of Psoriasis Association’s (IFPA). WPD 2016’s theme is “Breaking Barriers For People With Psoriasis!” to fight the barriers of prejudice, stigma and discrimination.

As part of WPD on Saturday October 29th 2016, LEO Pharma will launch a global digital campaign to empower psoriasis sufferers to better manage their psoriasis. To promote this important message, LEO Pharma Inc. Canada (LEO CA) is honoured to partner with Canadian psoriasis patients to share their journey on gaining confidence. Using the hashtag #PsoInControl, LEO CA encourages discussion among patients, supporters and healthcare to stay updated on available treatments.

About Psoriasis

Psoriasis has a variety of forms, with the most common one being psoriasis vulgaris (also referred as plaque psoriasis). Psoriasis vulgaris is estimated to affect approximately 1 million Canadians, with men and women equally likely to be affectedfootnote 11. It is a long-lasting, debilitating disease, and patients with inadequately managed psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancerfootnote 22.  Psoriasis is characterized by thick, red, scaly, patches (plaques) on the skin, that can. be itchy. Symptoms can vary from mild to severe, covering very small or extensive areas of the body.

How to be #PsoInControl

Psoriasis is a long-lasting disease, which alternates between periods of improving symptoms and worsening symptoms, but can be managed. A better understanding of the various treatment options could lead to a more confident approach at managing symptoms more effectively. 

Show us that you are #PsoInControl and join our Thunderclap.

About LEO Pharma A/S

LEO Pharma is a global healthcare company that offers care solutions within dermatology and thrombosis to patients in more than 100 countries around the world.

Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to delivering products to people with skin conditions and thrombosis.

LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.

For more information, visit

For more information about our patient support program QualityCare™, visit

Subscribe to our YouTube channel:

Follow us on Twitter:

Visit us at LinkedIn:


  1. accessed on October 4, 2016
  2. Taraska V, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) exhibits no impact on the HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris: a multicenter, single-arm, Phase II, 4-week MUSE study. Presented at the Skin Disease Education Foundation’s 15th Annual Las Vegas Dermatology Seminar & the 11th Annual SDEF Psoriasis Forum, October 30-November 1, 2014